Investor Claims Spark Investigation into Capricor Therapeutics
Investigation Overview of Capricor Therapeutics, Inc.
Pomerantz LLP is currently looking into claims on behalf of investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR). This investigation seeks to determine whether the company or certain executives have engaged in practices that could be deemed unlawful, particularly concerning securities fraud.
Details of the Allegations
The investigation arises from concerns regarding the company's conduct and the implications for its investors. If wrongdoing is confirmed, it may impact investors significantly, making their rights to recovery a focus for legal action.
Impact of Recent FDA Announcements
On May 5, 2025, Capricor released a statement following a crucial mid-cycle review meeting with the U.S. Food and Drug Administration (FDA). The company was pursuing a Biologics License Application (BLA) for their investigational cell therapy, deramiocel, intended to treat Duchenne muscular dystrophy (DMD) cardiomyopathy. The FDA confirmed its plan to convene an advisory committee meeting to discuss the BLA.
Market Reaction to FDA Withdrawal
The announcement led to a considerable decline in Capricor's stock, which dropped $3.00 or approximately 29.13% on May 6, 2025, closing at $7.30 per share. However, the situation escalated further when, on June 20, 2025, it was reported that a newly appointed head of the FDA unit had canceled this advisory meeting due to concerns regarding the effectiveness and safety of deramiocel.
Stock Price Decline
This cancellation resulted in another significant stock price drop. On the day of the news, shares fell by $3.68 or 30.82%, closing at $8.26 per share. Such substantial fluctuations have raised alarms about the company's operational integrity and investor confidence.
About Pomerantz LLP
Pomerantz LLP is highly regarded in corporate and securities litigation. Founded over 85 years ago, the firm has built a reputation for its advocacy in class actions related to securities fraud and breach of fiduciary duty. With a history of recovering billions for investors, Pomerantz is dedicated to protecting shareholder rights.
Contact for More Information
Investors interested in learning more about their rights related to this investigation are encouraged to reach out. Danielle Peyton can be contacted at 646-581-9980, ext. 7980, or via email. She can provide further details about the ongoing investigation and advice for affected investors.
Frequently Asked Questions
What is the recent investigation about Capricor Therapeutics?
The investigation by Pomerantz LLP focuses on potential securities fraud by Capricor and its executives affecting investors' rights.
What triggered the stock price drops for Capricor?
Significant stock price drops followed announcements about the FDA’s mid-cycle review and subsequent meeting cancellations regarding their investigational therapy.
Who can I contact for more information?
For inquiries, investors can contact Danielle Peyton at Pomerantz LLP at 646-581-9980, ext. 7980.
What is Capricor Therapeutics' focus?
Capricor Therapeutics specializes in developing therapies for conditions like Duchenne muscular dystrophy.
How does Pomerantz LLP support investors?
Pomerantz LLP represents investors in class actions, protecting their rights and seeking damages due to securities fraud and misconduct.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.